PolyPid Ltd. (PYPD) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Polypid Ltd..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.217 Greetings and welcome to Polypeed's first quarter 2026 earnings 00:00:05.217 -- 00:00:11.004 conference call. At this time, participants are in a listen-only mode. 00:00:11.004 -- 00:00:16.110 As a reminder, this call is recorded and I would now like to introduce your host 00:00:16.110 -- 00:00:21.177 for today's conference, Yehuda Libra from ARX Investor 00:00:21.177 -- 00:00:25.439 Relations. Mr. Libra, you may begin. 00:00:27.976 -- 00:00:33.105 Thank you, Operator, and thank you all for joining PolyPID's first quarter 2026 earnings 00:00:33.105 -- 00:00:38.253 conference call. Joining me on the call today will be Dikla Chachkis-Axelbrad, 00:00:38.253 -- 00:00:44.103 Chief Executive Officer of PolyPID, Johnny Misalawin, PolyPID's Chief Financial Officer, 00:00:44.103 -- 00:00:47.229 and Ori Warshavsky, Chief Operating Officer, U.S. 00:00:47.229 -- 00:00:51.977 of PolyPID. Earlier today, PolyPID released its financial results for the three months 00:00:51.977 -- 00:00:54.554 ended March 31st, 2026. 00:00:54.554 -- 00:00:58.765 A copy of the press release is available on the Investors section of the company's website 00:00:58.765 -- 00:01:01.166 at www.polypid.com. 00:01:02.213 -- 00:01:05.983 I'd like to remind you that on this call, management will make forward-looking statements 00:01:05.983 -- 00:01:08.375 within the meaning of the federal securities laws. 00:01:08.375 -- 00:01:12.741 For example, management is making forward-looking statements when discussing the company's 00:01:12.741 -- 00:01:17.867 regulatory strategy, including the expected completion of the rolling new drug application, 00:01:17.867 -- 00:01:23.374 or NDA, submission for DPLEX-100. Management may also discuss the company's planned engagements 00:01:23.37...